Komodo Health unveils MapEnhance, a new centralized network of specialty data partners

Komodo Health unveiled MapEnhance, a new feature leveraging a network of specialty data partners connecting into the company's platform.

MapEnhance builds on Komodo’s Healthcare Map, a de-identified data set on 330 million U.S. patients, by combining it with exclusive data curated by partner organizations. The partners publicly announced this week include Invitae, PointClickCare and Trio Health. 

The goal is to offer visibility into a multi-dimensional, real-world view of clinical events and patient populations at a level of granularity not previously available. With MapEnhance, users can quickly perform comprehensive analytics, develop higher-performing predictive models and conduct research, Komodo says.

“We’ve been on this mission of stitching together patient journeys,” Arif Nathoo, M.D., co-founder and CEO of Komodo Health, told Fierce Healthcare. “MapEnhance is a way to bring others to the table who have very specific views into certain populations and ensure those populations are represented in the data.”

MapEnhance screenshot
MapEnhance builds on Komodo’s Healthcare Map (Komodo Health)

The partnerships were years in the making, per Nathoo. More partners are expected to be publicly announced in the future. Most of the data in MapEnhance will be available to Komodo customers for an additional fee, which will depend on the scale each is interested in. 

Because the data will be integrated, cleaned and standardized, that will develop faster and timelier insights to users. The idea is for healthcare and life science stakeholders to migrate away from legacy data vendors that are inefficient and costly, Nathoo said.

The data available with MapEnhance include: 

Precision molecular diagnostics: Features a range of proprietary cytogenetics, genetics tests and others focused on multiple therapeutic areas like cancer, cardiology, neurology, pediatric genetics, metabolic disorders, immunology and hematology. 

High-volume standard lab diagnostics: Said to be derived from the largest clinical lab providers in the U.S., including inpatient and outpatient lab tests, to drive earlier visibility into diagnosis and disease progression. 

Electronic medical records: Offers unique visibility into clinical encounters, with observations captured at the point of care, including characteristics of patients with complex conditions like autoimmune diseases, diabetes, Alzheimer’s and more. 

Inpatient and outpatient facility chargemasters: Provides visibility into individual components of cost and utilization associated with episodes of care across hospital settings. 

“This is a huge step forward to bring together comprehensive clinical and cost-of-care insights to deliver real-world treatment recommendations,” Brent Clough, CEO of Trio Health, said in the announcement.

Additionally, having third-party data overlap with Komodo’s massive data set allows it to be checked for sampling bias, Nathoo explained. That information will then be presented to users before they choose whether to buy and use third-party data via MapEnhance so they can make a rational, informed decision based on how equitable and representative it is.